A lawsuit against the genomics company "imposes top-down restrictions" rather than "establishing clear rules" or "letting ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Anne Wojcicki, co-founder and former CEO of 23andMe, has bid to buy back the genetic testing platform, which was pronounced ...

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Japan’s Nippon Steel has completed its purchase of U.S. Steel after reaching a national-security agreement with the White ...

23andMe looked set to be acquired by biopharma group Regeneron after a $256 million takeover deal was agreed last month, but Wojcicki now says she wants to table a new offer backed by "a Fortune ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

More reports of Kroger-owned locations closing across the country are appearing after the company said it will be shuttering ...

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million Global News Select May 19, 2025, 11:55:00 AM. Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 ...

ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar ...